Danish manufacturer Novo Nordisk has reportedly approached Global Blood Therapeutics Inc., a U.S. biotech company, to discuss a possible acquisition, according to a Reuters story.
Global Blood Therapeutics would provide a host of blood disease treatments under development, and would be a big score for Novo Nordisk. The biotech company is said to be working with an investment bank to discuss its options, but there is no guarantee negotations will proceed.
Read the Reuters article